7 Best Peptides for Diabetic Neuropathy

What to Know Before Choosing a Peptide for Diabetic Neuropathy

Diabetic neuropathy is nerve damage driven by prolonged high blood sugar, and it is the most common complication of diabetes. The burning pain, tingling, and numbness it produces are notoriously difficult to manage with standard medications. That is why a growing number of people dealing with this condition have started looking beyond pregabalin and duloxetine toward peptides, compounds that can target the underlying biology of nerve damage rather than simply covering the symptoms.

This guide lists the peptides that people actually use or are actively discussing for diabetic neuropathy. That is the whole standard for inclusion. A compound earns a spot because real people reach for it, whether it is an investigational drug with Phase II trial data, something a telehealth clinic can prescribe, or a research-only compound with no regulatory standing. Evidence strength is stated honestly inside each entry rather than used as a filter. A compound with a completed clinical trial sits in the same list as one whose only record is user-reported experience, because both are part of the real conversation, and a reader navigating that conversation deserves to see the full picture.

The entries are numbered by how prominently each compound appears in the research and in documented real-world use for diabetic neuropathy. That ordering is not a recommendation of one compound over another. The right choice depends on your specific situation, your type of diabetes, which nerve pathways are affected, and a conversation with a qualified clinician. What this guide does is give you an honest map of the field so that conversation can start from an informed place.

1. ARA-290: The Most Clinically Studied Option for Nerve Regrowth

ARA-290, also called cibinetide, is a synthetic nine-amino acid peptide engineered from a specific surface region of erythropoietin, the hormone best known for stimulating red blood cell production. The design removes the blood-building effects entirely while preserving the tissue-protective signaling, which eliminates the cardiovascular risks that make standard erythropoietin therapy dangerous at higher exposures.

Its mechanism centers on a receptor called the Innate Repair Receptor, or IRR, a cell-surface complex that is entirely distinct from the erythropoietin receptor. When ARA-290 binds to the IRR, it triggers anti-inflammatory, neuroprotective, and pro-regenerative signaling. In the context of diabetic neuropathy, that means reduced neurological inflammation, improved microvascular circulation to damaged nerves, and support for the regrowth of small nerve fibers, the thin unmyelinated fibers that are typically the first casualties of chronically high blood sugar.

ARA-290 is the only compound on this list with published Phase II clinical trial data specifically in diabetic neuropathy. That trial, conducted in patients with Type 2 diabetes and confirmed peripheral neuropathy, reported significant improvements in neuropathic symptoms and nerve function, including pain reduction and improved nerve conduction velocities. A separate 28-day safety trial found no clinically significant adverse events, no changes in liver, kidney, or hematological markers, and an adverse event profile comparable to placebo. The most striking finding from the clinical work is that measurable small fiber nerve regrowth was observed in human subjects within 28 days, a result that sets ARA-290 apart from compounds that primarily manage symptoms rather than rebuild structure.

Across neuropathy-focused communities, ARA-290 is the most consistently discussed peptide for active nerve pain from diabetes. Users typically report meaningful pain relief beginning somewhere between three and twelve days into a treatment cycle. A recurring pattern in those accounts is that benefits fade within one to two weeks after stopping, which leads many people to run repeated cycles rather than treating it as a single course. Cost is the most common complaint: ARA-290 is consistently described as expensive, and that expense is a real barrier to long-term use. Some users have combined it with BPC-157 and TB-500 and reported enhanced outcomes, though no controlled data exists for that combination.

The compound's development path is complicated. Phase II results were positive, and Phase III trials were discussed, but Araim Pharmaceuticals, the company that developed ARA-290, has since shut down. The compound is not FDA-approved, there are no approved clinical guidelines for its use, and access runs through specialized clinics, research settings, or research-chemical channels. Anyone considering it should discuss both the access pathway and their specific neuropathy presentation with a qualified healthcare provider.

2. BPC-157: For Peripheral Nerve Repair and Microvascular Support

BPC-157 is a pentadecapeptide, a chain of fifteen amino acids, derived from a protein sequence found in gastric juice. It has accumulated the largest body of preclinical nerve-repair research of any compound on this list, gathered across a range of injury models rather than diabetic neuropathy specifically. Its relevance to neuropathy from diabetes comes from two overlapping mechanisms: it promotes angiogenesis, the formation of new blood vessels, which directly addresses the endoneurial ischemia that starves damaged nerves of oxygen and nutrients, and it supports axonal regeneration while reducing inflammatory signaling along nerve pathways.

In sciatic nerve crush models, BPC-157 improved functional recovery indices by roughly 34 to 42 percent and enhanced nerve conduction, results that are cited frequently in regenerative medicine contexts as evidence of genuine nerve-repair activity. No large-scale human trials have been published for diabetic neuropathy specifically. The evidence here is preclinical and extensive by the standards of research peptides, but it is animal-model data rather than human trial data, and that distinction matters when comparing it to ARA-290's clinical record.

In the neuropathy community, BPC-157 tends to occupy a different role than ARA-290. Where ARA-290 is discussed primarily for its direct effect on nerve pain and small fiber regeneration, BPC-157 comes up more often as a foundational repair compound, something people layer in for its angiogenic and anti-inflammatory properties rather than expecting a fast pain-reduction effect. It is also used off-label across a wide range of conditions beyond neuropathy, which makes it more accessible through research-chemical and some telehealth channels. BPC-157 is not FDA-approved, and no approved dosing guidelines exist for human use.

3. C-Peptide: For Type 1 Diabetic Neuropathy Specifically

C-Peptide is a 31-amino acid fragment that connects the two chains of proinsulin before insulin is cleaved into its active form. In people without diabetes, the pancreas releases C-Peptide and insulin together in roughly equal amounts. In Type 1 diabetes, where the beta cells that produce both are destroyed by the immune system, C-Peptide becomes effectively absent. That deficiency is the clinical rationale for this compound's use in neuropathy, and it is also the reason C-Peptide is the one entry on this list that applies almost exclusively to Type 1 diabetes.

Its mechanism runs through several pathways simultaneously. C-Peptide binds to receptors on endothelial and nerve cell membranes, activating a cascade that stimulates endothelial nitric oxide synthase, which in turn increases nitric oxide and improves blood flow through the tiny vessels that supply nerve fibers. It also directly stimulates the sodium-potassium pump, whose activity is suppressed by the polyol pathway under high blood sugar, and restoring that pump helps normalize the electrical properties of damaged nerves. A third arm of the mechanism involves stimulating the expression of nerve growth factor and insulin-like growth factor 1, both of which support the structural maintenance and repair of axons.

The human trial data for C-Peptide in Type 1 diabetic neuropathy is mixed but real. A double-blind, placebo-controlled, randomized multicenter trial enrolling 161 Type 1 diabetes patients with defined diabetic sensorimotor peripheral neuropathy found a statistically significant improvement in sural nerve sensory conduction velocity in the C-Peptide group. A later Phase 2b trial using a long-acting PEGylated form, enrolling 139 patients over twelve months, showed the PEGylated version improved nerve conduction within the treatment group but failed to produce a statistically significant difference versus placebo on the primary endpoint. The honest read is that C-Peptide has the most developed human evidence base for diabetic neuropathy of any compound here aside from ARA-290, but the results are inconsistent across trials and the benefit appears concentrated in early-stage neuropathy in Type 1 patients. C-Peptide is not FDA-approved, no commercial formulation is available, and there is no meaningful evidence for its use in Type 2 diabetic neuropathy.

4. MOTS-c: For the Mitochondrial Pathway of Nerve Damage

MOTS-c is a peptide encoded not in the cell nucleus but in the mitochondrial genome, specifically in the 16S ribosomal RNA sequence. It belongs to a family of mitochondrial-derived peptides, of which Humanin is the other best-known member. Its relevance to diabetic neuropathy comes from what it targets: the mitochondrial dysfunction that sits at the heart of hyperglycemic nerve damage.

When blood sugar stays elevated for years, the mitochondria inside nerve cells, the organelles that generate energy for those cells, begin to fail. Think of them as the power plants of the cell: when they malfunction, the nerve fiber runs on a failing generator rather than at full capacity, and its ability to transmit signals and repair itself degrades progressively. MOTS-c addresses this by activating the AMPK/PGC-1alpha pathway, a metabolic signaling axis that promotes mitochondrial biogenesis, meaning the creation of new mitochondria, and restores energy metabolism. It also inhibits inflammatory signaling that compounds nerve damage downstream of the mitochondrial failure.

In a streptozotocin-induced painful diabetic neuropathy mouse model, MOTS-c significantly reduced both mechanical allodynia, pain triggered by normally non-painful touch stimuli, and thermal hyperalgesia, an exaggerated pain response to heat. These are two of the most characteristic symptoms of diabetic peripheral neuropathy, and addressing both in a preclinical model is meaningful. No human clinical trials for MOTS-c in diabetic neuropathy have been published as of 2026. What exists is that animal research alongside growing community interest in mitochondrial peptides for metabolic and neurological conditions. The mechanism is well-matched to the underlying biology of hyperglycemic nerve damage, which makes MOTS-c a compound worth tracking as the research matures.

5. GHK-Cu: For Oxidative Stress Protection in Damaged Nerves

GHK-Cu is a naturally occurring plasma tripeptide, three amino acids, glycine, histidine, and lysine, complexed with copper. It has a broad role in tissue repair, anti-inflammatory signaling, and antioxidant defense. Its connection to diabetic neuropathy runs through oxidative stress, the process by which reactive oxygen species damage nerve fibers under chronic hyperglycemic conditions.

High blood sugar drives excess glucose through metabolic pathways that generate damaging free radicals as a byproduct. Those free radicals accumulate and attack nerve cell structures, contributing to the axonal degeneration that defines diabetic peripheral neuropathy. GHK-Cu addresses this by activating the Nrf2 pathway, a master regulator of the body's antioxidant response. Nrf2 functions like a dial that turns up the cell's own protective enzyme production: when it is activated, cells generate more antioxidant capacity, reducing the reactive oxygen species burden on nerve tissue. In preclinical animal models, GHK-Cu has been shown to partially normalize nerve conduction velocity, a direct functional measure of nerve health.

No human clinical trials for GHK-Cu in diabetic neuropathy have been published as of 2026. Its use in this context is supported by the animal research described above and by the broader scientific consensus that oxidative stress is a primary driver of nerve damage in hyperglycemic conditions, which makes the mechanism highly plausible even without a human trial to confirm it. GHK-Cu is widely available in both topical and injectable forms and is among the more accessible compounds on this list, though the available evidence for diabetic neuropathy specifically remains at the preclinical level.

6. Cerebrolysin: For Neurotrophic Support and Myelination

Cerebrolysin is not a single peptide but a mixture, derived from porcine brain tissue, that contains fragments of several neurotrophic factors including brain-derived neurotrophic factor, nerve growth factor, ciliary neurotrophic factor, and glial cell line-derived neurotrophic factor. Those factors are signaling proteins the nervous system uses to maintain, repair, and grow nerve fibers. In the context of diabetic neuropathy, where neurotrophic factor levels are chronically suppressed by hyperglycemia, delivering a concentrated mixture of their active fragments has a straightforward biological rationale.

For diabetic neuropathy specifically, Cerebrolysin has been studied in mouse models, where it produced dose-dependent improvements in myelinated nerve fiber diameter and cross-sectional area. Myelin is the protective sheath that coats nerve fibers and is essential for rapid signal conduction, and its loss is one of the hallmarks of advanced diabetic peripheral neuropathy. A compound that supports myelination and fiber morphology addresses a real structural feature of the disease, not just the symptomatic surface of it. Outside diabetic neuropathy, Cerebrolysin's broader clinical use in stroke, traumatic brain injury, and Alzheimer's disease has been studied in randomized controlled trials in Europe and Asia, where it is an approved therapy for certain neurological conditions. That clinical history gives it a more established safety profile than most compounds in this space, even though diabetic neuropathy-specific evidence remains at the preclinical level.

Cerebrolysin is not FDA-approved for diabetic neuropathy, but it is available as a licensed neurological drug in some countries and is accessible through research channels. Its presence in neuropathy discussions tends to be less prominent than ARA-290 or BPC-157, but it appears consistently in conversations about compounds that address the neurotrophic factor deficiency component of nerve damage, which is a real and often underaddressed aspect of managing diabetic neuropathy.

7. Humanin: Mitochondrial Neuroprotection with Limited Neuropathy-Specific Data

Humanin is a mitochondrial-derived peptide encoded in the same 16S ribosomal RNA region of the mitochondrial genome as MOTS-c, and it is the founding member of that peptide family. Its known properties center on cytoprotection and anti-apoptotic activity, meaning it protects cells from dying under conditions of metabolic and oxidative stress. Because mitochondrial dysfunction is a central driver of nerve damage in chronic hyperglycemia, Humanin's biological profile makes it mechanistically relevant to diabetic neuropathy on paper.

In practice, the evidence linking Humanin specifically to diabetic neuropathy is thin. No clinical trial data has been published for this use as of 2026, and the preclinical research on Humanin in diabetic nerve damage is far less developed than what exists for MOTS-c, its mitochondrial sibling. Humanin's neuroprotective properties have been explored in broader contexts, including Alzheimer's disease research and metabolic disease models, but the diabetic neuropathy-specific record in the available literature is minimal. What exists is mechanistic plausibility and community interest among people researching mitochondrial peptides for neurological and metabolic conditions.

Humanin is included here because it is part of the active conversation in communities where people explore peptides for this goal, and its mitochondrial origin gives it a legitimate mechanistic rationale for the application. The evidence base specific to diabetic neuropathy is limited to general neuroprotective properties rather than any demonstrated effect on nerve damage from diabetes, and anyone considering it should enter that conversation with that limitation clearly in view.

How These Peptides Compare

Frequently Asked Questions

Are any of these peptides FDA-approved for diabetic neuropathy?

None of the peptides covered in this guide are FDA-approved specifically for treating diabetic neuropathy. FDA-approved options for the condition include oral medications like pregabalin and duloxetine, topical capsaicin for foot pain, and spinal cord stimulation devices. The peptides listed here are either investigational compounds, available through research channels, or in some cases approved for other indications in other countries but not cleared by the FDA for this specific use.

Does the type of diabetes I have matter when choosing a peptide?

Yes, and it matters significantly for at least one compound. C-Peptide is the clearest example: its mechanism depends on replacing a peptide that is naturally absent in Type 1 diabetes, and published trial evidence covers Type 1 patients only. There is no meaningful evidence for C-Peptide in Type 2 diabetic neuropathy. For other compounds like ARA-290 and BPC-157, the research and community use span both Type 1 and Type 2 patients, though the underlying biology of neuropathy does differ between the two conditions, and those differences can influence how a compound performs in practice.

How long does it typically take to notice any effect from these peptides?

Timelines vary considerably by compound and by person. ARA-290 has the most consistent community-reported data on onset, with many users noting meaningful pain relief within three to twelve days of starting a cycle. BPC-157 is generally described as a slower-acting repair compound rather than a fast pain reliever, with any functional changes emerging over weeks rather than days. For compounds where the evidence is limited to preclinical models, like MOTS-c and GHK-Cu, no reliable human timeline has been established. These are commonly reported ranges rather than predictions, and individual results depend on severity of neuropathy, blood glucose control, and other factors.

Do these peptides address underlying nerve damage or mainly manage symptoms?

It depends on the compound. ARA-290 is the most notable for showing evidence of structural nerve regeneration, specifically measurable small fiber regrowth in human subjects within 28 days, which suggests it affects underlying nerve architecture rather than simply masking pain. BPC-157's angiogenic and axonal regenerative properties in animal models point toward a similar repair-oriented mechanism. Most other compounds on this list are studied primarily for neuroprotection or symptom reduction rather than demonstrated fiber regrowth. Pain management and nerve repair are different endpoints, and no compound here has been shown to fully reverse established diabetic neuropathy in large-scale human trials.

Is blood glucose control still important when using these peptides?

Yes, and this is one of the most consistent messages across both the clinical literature and the neuropathy community. Community accounts consistently note that normalizing blood sugar produced significant improvement or resolution of neuropathic pain over months to years, independent of any peptide use. Peptides researched for diabetic neuropathy target specific pathways of nerve damage and may support repair or symptom relief, but none of them address the root cause of ongoing nerve damage if blood glucose remains elevated. Glucose management is the foundation; peptide research sits on top of it, not in place of it.

This content is for informational and educational purposes only. It does not constitute medical advice, diagnosis, or treatment recommendations. MyPeptidePal is not a medical provider. Always consult a qualified healthcare professional before starting, modifying, or stopping any health protocol, supplement regimen, or therapeutic intervention.

Sources

The information in this guide is drawn from the MyPeptidePal knowledge base, which brings together published research, clinical data, and documented real-world use of peptides for diabetic neuropathy in one place.